Compare SCLX & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | CDLX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 10.1M |
| IPO Year | 2020 | 2018 |
| Metric | SCLX | CDLX |
|---|---|---|
| Price | $0.57 | $1.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.43 |
| AVG Volume (30 Days) | ★ 73.1K | 60.7K |
| Earning Date | 12-01-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.13 |
| EPS | N/A | ★ N/A |
| Revenue | $30,253,000.00 | ★ $233,273,000.00 |
| Revenue This Year | $118.16 | N/A |
| Revenue Next Year | $186.31 | $12.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $0.55 |
| 52 Week High | $23.03 | $6.40 |
| Indicator | SCLX | CDLX |
|---|---|---|
| Relative Strength Index (RSI) | 8.42 | 23.58 |
| Support Level | N/A | $0.85 |
| Resistance Level | $7.77 | $1.16 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 2.80 | 9.57 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.